Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Has Obtained a Fair Price for Its Public Shareholders
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Has Obtained a Fair Price for Its Public Shareholders
MILWAUKEE, Aug. 15, 2024 /PRNewswire/ -- Ademi LLP is investigating Revance (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crown.
Ademi LLP正在调查Revance(纳斯达克:RVNC)是否存在违反信托责任和其他违法行为的可能性。
Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
点击这里了解如何加入我们的调查或拨打Guri Ademi的免费电话:866-264-3995。您不需要承担任何费用或义务。
Revance stockholders will receive only $6.66 per share in cash, representing a total enterprise value of $924 million. The transaction agreement unreasonably limits competing transactions for Revance by imposing a significant penalty if Revance accepts a competing bid. Revance insiders will receive substantial benefits as part of change of control arrangements.
Revance股东将仅获得每股6.66美元现金,其总企业价值为92400万美元。该交易协议通过对Revance施加巨额罚款的方式,不合理地限制了竞争交易。Revance内部人员将作为控制权变更安排的一部分获得巨大利益。
We are investigating the conduct of Revance's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
我们正在调查Revance董事会的行为,以及他们是否履行了对所有股东的信托责任。
If you own Revance common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or .
如果您拥有Revance普通股并希望获取更多信息,请通过[email protected]或免费电话:866-264-3995或联系Guri Ademi。
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
我们专门从事全国范围内有关收购、合并和个人股东权利的股东诉讼。欲了解更多信息,请随时与我们联系。律师广告。之前的业绩不保证类似的结果。
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
联系方式
Ademi LLP
Guri Ademi
免费电话:(866) 264-3995
传真:(414) 482-8001
SOURCE Ademi LLP
信息来源:Ademi LLP